abstract |
The present invention relates to agents that modulate interleukin-15 (“IL-15”) signaling or function (“therapeutic agents”) and the use of such agents to modulate immune function. The therapeutic targets the interaction of IL-15 with the receptor for the IL-15 and modulates IL-15-induced signaling. The therapeutic agent is formulated with a polymer such as poly-β-1- ♦ 4-N-acetylglucosamine for administration to a human subject capable of modulating IL-15-mediated immune function. [Selection] [Figure 1A-B] |